Current Report Filing (8-k)
June 17 2022 - 6:01AM
Edgar (US Regulatory)
0001335105
false
0001335105
2022-06-15
2022-06-15
0001335105
LIXT:CommonStockParValue0.0001PerShareMember
2022-06-15
2022-06-15
0001335105
LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember
2022-06-15
2022-06-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 15, 2022
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
delaware |
|
001-39717 |
|
20-2903526 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification
Number) |
680
East Colorado Boulevard, Suite 180
Pasadena
California 91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
LIXT |
|
The
Nasdaq Stock Market LLC |
Warrants
to purchase Common Stock, par value $0.0001 per share |
|
LIXTW |
|
The
Nasdaq Stock Market LLC |
Item
5.02. |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective
as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board
as an independent director.
Dr.
Bernards is a leader in the field of molecular carcinogenesis, working at the Netherlands Cancer Institute in Amsterdam. His research
focuses on identifying effective new drug combinations, new drug targets, and mechanisms of resistance to anti-cancer drugs. He has also
co-founded four biotechnology companies to bring his scientific discoveries to clinical oncology practice. He is a member of the Royal
Netherlands Academy of Sciences, an International Honorary Member of the American Academy of Arts and Sciences and an International Member
of the National Academy of Sciences (USA). Additionally, he is a fellow of the American Association for Cancer Research (AACR), and has
received the Princess Takamatsu Memorial Lectureship at this year’s AACR annual meeting where he presented new data on the unexpected
effectiveness of the Company’s lead compound, LB-100, when given with a variety of standard and investigational anti-cancer compounds
that have only modest activity on their own.
As
a new director, in lieu of a grant of stock options, Dr. Bernards will receive a one-time cash board fee of $100,000, payable immediately,
and an annual cash board fee of $40,000, payable quarterly.
Item
9.01. |
Financial
Statements and Exhibits. |
(d) There
is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 16, 2022 |
LIXTE
BIOTECHNOLOGY HOLDINGS, INC. |
|
|
|
|
By: |
/s/
JOHN S. KOVACH |
|
|
John
S. Kovach, Chief Executive Officer |
INDEX
TO EXHIBITS
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024